Notice of Interim Results and IMC Presentation

Summary by AI BETAClose X

CRISM Therapeutics Corporation will announce its Interim Results for the six months ended June 30, 2025, on Monday, September 15, 2025. Following the announcement, a live presentation will be hosted via Investor Meet Company on Tuesday, September 16, 2025, at 12.00pm BST. The presentation will include a discussion of the company's upcoming Phase 2 trial of irinotecan-ChemoSeed in glioblastoma, with the Phase 2 clinical trial expected to begin in Q1 2026. The Investor Meet Company presentation is open to all existing and potential shareholders, with questions able to be submitted pre-event until 9.00am BST on September 15, 2025.

Disclaimer*

UK 100

Latest directors dealings